Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOMENICA first-line trial in MMR-deficient advanced or recurrent endometrial cancer
2023-510097-14-00Phase 3Authorised
- Sponsor
- Arcagy-Gineco
- Start
- Apr 2022
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, open-label trial of dostarlimab, carboplatin and paclitaxel in endometrial adenocarcinoma (2 arms), sponsored by Arcagy-Gineco. Primary endpoint: Progression-free survival. Planned start Apr 2022; status: authorised.
02
Drugs
dostarlimabcarboplatinpaclitaxel
03
Conditions
endometrial adenocarcinoma
Beyond the preview
Go deeper on 2023-510097-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510097-14-00.